<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing administration and broadening therapeutic indications, building on the success of initial treatments like Soliris.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179393/pipeline-complement-c5-inhibitors-and-c5-receptor?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4kff54&amp;utm_campaign=2252525+-+Complement+C5+Inhibitors+%26+C5+Receptor+Antagonists+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Targeted+Immunotherapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Pipeline of Complement C5 Inhibitors &amp; C5 Receptor Antagonists">"Pipeline of Complement C5 Inhibitors &amp; C5 Receptor Antagonists"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about C5 Inhibitors &amp; C5 Receptor Antagonists provides an up-to-date competitor evaluation in the field of emerging therapy candidates in research and development targeting the complement C5 receptor or its ligand C5. This report will be prepared on demand within one working day upon order placement. The report lists active C5(R) targeted R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of C5 inhibitors &amp; C5 receptor antagonists by drug modality (mainly recombinant antibodies, but also proteins, peptides, RNA and small molecules). Complement component C5 is a pro-inflammatory protein that is part of the classical complement pathway. It plays a crucial role in the activation of C3 and C5, contributing to the inflammatory response associated with conditions like age-related macular degeneration (AMD). In the terminal pathway distal to C3, C5 is the critical component. C5 has some structural similarities to C3: C5 contains macroglobulin domains (MG1-MG8), the CUB domain, the C5d domain (structurally homologous to the TED of C3), the C5a domain (also called anaphylatoxin) and an extended linker region. Native human C5 is a naturally glycosylated (1.6%) polypeptide containing two disulfide-linked chains. C5 is essential for formation of the membrane attack complex (MAC) and is activated by all three pathways of complement activation. Eculizumab (Soliris) is a monoclonal antibody that binds C5 and blocks its proteolytic activation. Eculizumab was approved in 2007 for paroxysmal nocturnal hemoglobinuria (PNH), becoming the first complement inhibitor available to patients. With annual sales of more than US$ 6.53 bln in 2024, first and second generation C5 inhibitor antibodies Soliris and Ultomiris from AstraZeneca (acquired Alexion Pharmaceuticals) and Piasky have set the stage for next generation biosuperiors as well as biosimilars of a commercially successful and clinically effective treatment of complement C5 mediated diseases. New treatment modalities in development aim at improving the mode and frequency of administration as well as the scope of indications. Complement C5-mediated diseases are a group of disorders where the C5 protein of the complement system is implicated in tissue damage, autoimmune processes, and inflammation, including PNH, Atypical Hemolytic Uremic Syndrome (aHUS), Sickle Cell Disease (SCD), Myasthenia Gravis (MG), and Neuromyelitis Optica Spectrum Disorder (NMOSD). These conditions can involve the formation of the Membrane Attack Complex (MAC) or the release of anaphylatoxins like C5a, leading to symptoms such as anemia, blood clots, and kidney damage. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179393/pipeline-complement-c5-inhibitors-and-c5-receptor?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4kff54&amp;utm_campaign=2252525+-+Complement+C5+Inhibitors+%26+C5+Receptor+Antagonists+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Targeted+Immunotherapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/yor9na</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/OTFlMGE3MGItMzI0Yi00NjhhLTlmYjMtNjY3NTdlYWQwZTUwLTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn